Please assess the completion status of the following clinical trial:

Trial Title: 12-Month Open-Label Extension Study of Intepirdine (RVT-101) in Subjects With Alzheimer's Disease: MINDSET Extension

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Completed last on-treatment visit of the lead-in study RVT-101-3001~Exclusion Criteria:~* Any clinically relevant concomitant disease, which, in the opinion of the investigator, makes the subject unsuitable for inclusion in the study.

- Gender: ALL
- Minimum Age: 50 Years
- Maximum Age: 86 Years
- Healthy Volunteers: f

Study Arms:
- RVT-101 35 mg tablets (Type: EXPERIMENTAL): once daily, oral tablets

Based on this trial design, predict the completion outcome and termination type (if applicable).